GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GH Research PLC (FRA:1KA) » Definitions » Total Tax Payable

GH Research (FRA:1KA) Total Tax Payable : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is GH Research Total Tax Payable?

GH Research's Total Tax Payable for the quarter that ended in Mar. 2024 was €0.00 Mil.


GH Research Total Tax Payable Historical Data

The historical data trend for GH Research's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GH Research Total Tax Payable Chart

GH Research Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Tax Payable
- - - - -

GH Research Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Tax Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

GH Research Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.


GH Research Total Tax Payable Related Terms

Thank you for viewing the detailed overview of GH Research's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


GH Research (FRA:1KA) Business Description

Traded in Other Exchanges
Address
28 Baggot Street Lower, Dublin, IRL, D02 NX43
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. Its focus is on developing novel and proprietary 5-Methoxy-N,N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.

GH Research (FRA:1KA) Headlines

No Headlines